Tags

Type your tag names separated by a space and hit enter

Development of a recombinant vaccinia-rabies vaccine for oral vaccination of foxes against rabies.
Dev Biol Stand. 1992; 79:105-11.DB

Abstract

To improve both safety and stability of the vaccines used in the field to vaccinate foxes against rabies by the oral route, a recombinant vaccinia virus, expressing the immunizing G protein of rabies virus (VVTGg RAB-26D3 187 X P strain) has been developed. The c-DNA corresponding to the glycoprotein of the ERA strain of rabies virus has been inserted into the thymidine kinase (TK) gene of the vaccinia virus (Copenhagen strain). The efficacy of this recombinant strain was tested by the oral route, primarily in foxes. The duration of immunity conferred by the VVTGg RAB, a minimum of 12 months in cubs and 18 months in adult animals, corresponds to the length of protection required for fox vaccination in the field. VVTGg RAB innocuity was tested in foxes and in domestic animals as well as in numerous wild animal species that could compete with the red fox in consuming vaccine baits in Europe. During a minimum of 28 days post vaccination, neither clinical signs nor lesions were observed in any of the vaccinated animals. Moreover no transmission of immunizing amounts of the recombinant occurred in the red fox or the other species tested. To study the stability of the vaccine strain, baits containing the vaccine were placed in the field. Despite considerable variations of environmental temperatures, the VVTGg RAB titre remained stable after one month in the field. Since all the baits are taken within one month, it can be assumed that most of the animals taking the baits are effectively vaccinated.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Department of Virology Immunology, Faculty of Veterinary Medicine University of Liège, Sart Tilman, Belgium.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1286744

Citation

Pastoret, P P., and B Brochier. "Development of a Recombinant Vaccinia-rabies Vaccine for Oral Vaccination of Foxes Against Rabies." Developments in Biological Standardization, vol. 79, 1992, pp. 105-11.
Pastoret PP, Brochier B. Development of a recombinant vaccinia-rabies vaccine for oral vaccination of foxes against rabies. Dev Biol Stand. 1992;79:105-11.
Pastoret, P. P., & Brochier, B. (1992). Development of a recombinant vaccinia-rabies vaccine for oral vaccination of foxes against rabies. Developments in Biological Standardization, 79, 105-11.
Pastoret PP, Brochier B. Development of a Recombinant Vaccinia-rabies Vaccine for Oral Vaccination of Foxes Against Rabies. Dev Biol Stand. 1992;79:105-11. PubMed PMID: 1286744.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of a recombinant vaccinia-rabies vaccine for oral vaccination of foxes against rabies. AU - Pastoret,P P, AU - Brochier,B, PY - 1992/1/1/pubmed PY - 1992/1/1/medline PY - 1992/1/1/entrez SP - 105 EP - 11 JF - Developments in biological standardization JO - Dev Biol Stand VL - 79 N2 - To improve both safety and stability of the vaccines used in the field to vaccinate foxes against rabies by the oral route, a recombinant vaccinia virus, expressing the immunizing G protein of rabies virus (VVTGg RAB-26D3 187 X P strain) has been developed. The c-DNA corresponding to the glycoprotein of the ERA strain of rabies virus has been inserted into the thymidine kinase (TK) gene of the vaccinia virus (Copenhagen strain). The efficacy of this recombinant strain was tested by the oral route, primarily in foxes. The duration of immunity conferred by the VVTGg RAB, a minimum of 12 months in cubs and 18 months in adult animals, corresponds to the length of protection required for fox vaccination in the field. VVTGg RAB innocuity was tested in foxes and in domestic animals as well as in numerous wild animal species that could compete with the red fox in consuming vaccine baits in Europe. During a minimum of 28 days post vaccination, neither clinical signs nor lesions were observed in any of the vaccinated animals. Moreover no transmission of immunizing amounts of the recombinant occurred in the red fox or the other species tested. To study the stability of the vaccine strain, baits containing the vaccine were placed in the field. Despite considerable variations of environmental temperatures, the VVTGg RAB titre remained stable after one month in the field. Since all the baits are taken within one month, it can be assumed that most of the animals taking the baits are effectively vaccinated.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0301-5149 UR - https://www.unboundmedicine.com/medline/citation/1286744/Development_of_a_recombinant_vaccinia_rabies_vaccine_for_oral_vaccination_of_foxes_against_rabies_ L2 - https://medlineplus.gov/rabies.html DB - PRIME DP - Unbound Medicine ER -